半边天NEWOMEN品牌怎么样 申请店铺

我要投票 半边天NEWOMEN在乌鸡白凤丸行业中的票数:647 更新时间:2026-02-01
半边天NEWOMEN是哪个国家的品牌?「半边天NEWOMEN」是 江西半边天药业有限公司 旗下著名品牌。该品牌发源于香港,由创始人翁汉辉在1998-04-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力半边天NEWOMEN品牌出海!将品牌入驻外推网,定制半边天NEWOMEN品牌推广信息,可以显著提高半边天NEWOMEN产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

半边天NEWOMEN怎么样

始于1998年,香港半边天药业国际集团旗下,专注妇科中成药、保健品的研发、生产、销售的制药公司


半边天药业国际集团(香港)有限公司成立于一九九八年四月,目前拥有江西半边天药业有限公司、深圳市半边天保健品有限公司、深圳市金药坊医药有限公司等多家下属企业,并在江西省泰和经济开发区建有占地十六万余平方米的生产基地——半边天药业国际集团工业城,固定资产规模达人民币2亿多元,其国内总部设在深圳。

半边天药业国际集团本着“专心造好药,健康半边天”的经营宗旨,专注妇科中成药、保健品的研发、生产、销售,已形成具有调经类、乳腺类、补血类、消炎类、排毒类等多种功能的妇科产品线,主要品种有国家中药保护品种和新药复方乌鸡口服液、乳宁丸、阿胶益寿口服液、乌鸡白凤丸、芦荟胶囊、妇舒洁洗液、妇炎康片等。

半边天药业国际集团下属的成员企业江西半边天药业拥有:口服液、糖浆、蜜丸、水丸、洗液等多条具有国内专业水平的生产线;生产能力10亿元以上;2004年和2009年两次通过国家药监局的GMP认证。目前正在建设中的二期工程包括了片剂、胶囊剂、颗粒剂等多种剂型。二期工程预计2012年完工建成。

半边天药业国际集团坚持以市场为导向,下属成员企业深圳金药坊医药有限公司是集团公司的营销中心,已于二OO四年六月顺利通过GSP认证,目前已建成以深圳为中心,辐射华南、华东、中南、西南的销售网络,在广东、广西、云南、贵州、湖南、湖北、重庆、四川、江苏、江西、安徽、浙江、山东等二十多个省、直辖市、自治区设立了二百多个营销分支机构,建立了一千多人的专业销售队伍。

半边天药业国际集团注重科技创新,与国内外多家医药研究机构建立了密切合作关系,实现了产品研发、信息交流、市场开拓、人才培养友好互动,生产、储备、研制、构想齐头并进的良好发展格局。

未来,半边天药业国际集团将继续“专业妇科品牌”的道路,通过并购、合作等多种途径,丰富产品群,扩大销售规模,进一步提升品牌影响力,积极寻求上市,实现中国医药市场妇科品牌的战略目标。


Started in 1998, half sky Pharmaceutical International Group (Hong Kong) Co., Ltd., a pharmaceutical company under half sky Pharmaceutical International Group in Hong Kong, which focuses on the research and development, production and sales of Chinese medicine for gynecology and health care products, was founded in April 1998. At present, it has Jiangxi half sky Pharmaceutical Co., Ltd., Shenzhen half sky health care products Co., Ltd., Shenzhen Golden Pharmaceutical Co., Ltd., etc There are more than 160000 square meters of production base - banbiantian Pharmaceutical International Group Industrial City in Taihe Economic Development Zone of Jiangxi Province, with fixed assets of more than 200 million yuan. Its domestic headquarters is located in Shenzhen. Based on the business tenet of "concentrate on making medicine, healthy half sky", banbiantian Pharmaceutical International Group focuses on the R & D, production and sales of Chinese traditional medicine and health care products in gynecology. It has formed a gynecology product line with multiple functions such as menstrual regulation, breast, blood tonic, anti-inflammatory, detoxification, etc. the main varieties are national traditional Chinese medicine protection varieties and new compound Wuji oral liquid, runing pill, a Jiaoyishou oral liquid, Wuji Baifeng pill, aloe capsule, fushujie lotion, Fuyankang tablet, etc. Jiangxi banbiantian Pharmaceutical Co., Ltd., a member enterprise of banbiantian Pharmaceutical International Group, has many production lines with domestic professional level, such as oral liquid, syrup, honey pill, water pill, lotion, etc.; the production capacity is more than 1 billion yuan; in 2004 and 2009, it passed the GMP certification of the State Food and Drug Administration twice. At present, the second phase project under construction includes tablet, capsule, granule and other dosage forms. The second phase of the project is expected to be completed in 2012. Banbiantian Pharmaceutical International Group adheres to the market orientation, and its subordinate member company Shenzhen jinyaofang Pharmaceutical Co., Ltd. is the marketing center of the group company. It has successfully passed the GSP certification in June 2004. At present, it has established a sales network with Shenzhen as the center, radiating South China, East China, Central South China and southwest China. It is located in Guangdong, Guangxi, Yunnan, Guizhou, Hunan, Hubei, Chongqing and Siyuan Sichuan, Jiangsu, Jiangxi, Anhui, Zhejiang, Shandong and more than 20 provinces, municipalities and autonomous regions have set up more than 200 marketing branches and established a professional sales team of more than 1000 people. Banbiantian Pharmaceutical International Group attaches great importance to scientific and technological innovation, and has established close cooperation with a number of pharmaceutical research institutions at home and abroad. It has achieved a good development pattern of product research and development, information exchange, market development, friendly interaction of talent training, and simultaneous development of production, reserves, research and ideas. In the future, banbiantian Pharmaceutical International Group will continue to be a "professional gynecological brand", enrich the product group, expand the sales scale, further enhance the brand influence, actively seek listing, and achieve the strategic goal of gynecological brand in China's pharmaceutical market through M & A, cooperation and other ways.

本文链接: https://brand.waitui.com/fae4e258c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

苹果人工智能团队再现离职潮,多名研究员转投Meta和谷歌

除了失去一位Siri高管外,苹果公司近几周又流失至少四位人工智能研究员,这些员工转投了包括Meta和谷歌DeepMind在内的雇主。最新离职人员包括Yinfei Yang、Haoxuan You、Bailin Wang和Zirui Wang。据报道,Yang离职创办新公司,而You和Bailin Wang加入Meta。You进入Meta的“超级智能”研究部门。Zirui Wang将加入谷歌DeepMind,该团队正协助苹果打造将支持新功能的核心人工智能模型。这包括今年将发布的新版Siri语音助手所依托的技术。(财联社)

2小时前

零跑汽车:1月交付32059台,同比增长27%

36氪获悉,据零跑汽车消息,零跑汽车1月交付32059台,同比增长27%。

2小时前

韩国1月出口同比增34%

韩国产业通商部2月1日发布数据显示,韩国1月出口额同比增加33.9%,为658.5亿美元,创下历史同期最高纪录。出口品目中,韩国最大出口产品半导体出口额同比大增103%,为205亿美元,连续两个月突破200亿美元,带动1月出口总额增加。同期,进口额同比增加11.7%,为571亿美元。由此,1月贸易收支实现87亿美元顺差。单月贸易收支连续12个月实现顺差。(界面)

2小时前

Waymo拟募资约160亿美元,估值接近1100亿美元

据知情人士透露,Alphabet公司旗下自动驾驶子公司Waymo计划在新一轮融资中募资约160亿美元,融资完成后该子公司估值将接近1100亿美元。知情人士表示,母公司将为这家自动驾驶出行公司注资约130亿美元,其余资金来自红杉资本、数字天空技术集团、龙跃资本等新晋投资方。知情人士还称,Waymo有望在2026年2月完成本轮融资。该公司上一轮融资于2024年10月完成,由旗下拥有谷歌的Alphabet领投,彼时估值已超450亿美元。(新浪财经)

2小时前

SpaceX申请部署100万颗卫星,拟建太阳能卫星AI数据中心

据美国联邦通信委员会备案文件显示,埃隆・马斯克旗下的SpaceX计划发射由 100 万颗卫星组成的卫星星座,这些卫星将绕地运行,并利用太阳能为人工智能数据中心提供电力。(新浪财经)

2小时前

本页详细列出关于半边天NEWOMEN的品牌信息,含品牌所属公司介绍,半边天NEWOMEN所处行业的品牌地位及优势。
咨询